AB0779 Eosinophilic myositis and rheumatoid arthritis as first manifestation in a patient carrying myotonic dystrophy type 2 (CCTG)n expenssion of ZNF9 gene
A. Meyer(Laboratoire de Physique de Clermont Auvergne), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Rose‐Marie Javier(Laboratoire National de Référence), A Echániz(Hôpitaux Universitaires de Strasbourg), Christelle Sordet, Emmanuel Chatelus(Laboratoire National de Référence), Bernard Gény(Université de Strasbourg), Béatrice Lannes, Jacques‐Eric Gottenberg(Centre National de la Recherche Scientifique), Arnaud Theulin(Hôpitaux Universitaires de Strasbourg)
Cited by 0
Related Papers
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)
|Annals of the Rheumatic Diseases|2012|207